Eye Disease News and Research

RSS
Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.
New gene editing technique could hinder retinal degeneration in rats with inherited blindness

New gene editing technique could hinder retinal degeneration in rats with inherited blindness

Presence of myopia significantly affects muscles used in focusing lens of the eye

Presence of myopia significantly affects muscles used in focusing lens of the eye

Researchers test new concept in type 2 diabetes patients going into remission

Researchers test new concept in type 2 diabetes patients going into remission

Adverse environmental changes present potential health hazards to eyes

Adverse environmental changes present potential health hazards to eyes

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

HITLAB selects five finalists for HITLAB World Cup

HITLAB selects five finalists for HITLAB World Cup

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

UCSF scientists identify eye drop chemical that may reverse cataracts

UCSF scientists identify eye drop chemical that may reverse cataracts

Study suggests need for specific treatment options for adolescents with onset type 2 diabetes

Study suggests need for specific treatment options for adolescents with onset type 2 diabetes

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Study identifies potential new approaches to curing parasitic diseases

Study identifies potential new approaches to curing parasitic diseases

Healthy food can help low-income people better control their diabetes

Healthy food can help low-income people better control their diabetes

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Saint Louis University ophthalmologist offers tips to manage night vision issues

Saint Louis University ophthalmologist offers tips to manage night vision issues

NYSCF conference to focus on translational stem cell and neuroscience research

NYSCF conference to focus on translational stem cell and neuroscience research

NAM announces election of three new members from UC San Diego School of Medicine

NAM announces election of three new members from UC San Diego School of Medicine

Allergan completes acquisition of AqueSys

Allergan completes acquisition of AqueSys

QUT's Professor Joanne Wood wins 'Nobel Prize' of international optometry

QUT's Professor Joanne Wood wins 'Nobel Prize' of international optometry

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.